Compare Adaptive Biotechnologies Corp (ADPT) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs VanEck Semiconductor ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while VanEck Semiconductor ETF trades at $585.47. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, VanEck Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SMH | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $668.91 |
52-Week Low | $12.30 | $286.43 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
SMH trades at $588.23, up 3.31% today, with a neutral technical signal and mixed momentum indicators. The ETF faces headwinds from semiconductor sector volatility and recent downgrades, while institutional interest remains active with new stakes from firms like Ferguson Shapiro LLC. Support and resistance levels suggest consolidation near current prices, with key levels at $560 support and $587 resistance.
Outlook is cautious due to sector rotation and AI-driven volatility, though long-term demand for semiconductors remains strong. Risks include tariff impacts and competitive ETF performance, but strategic positioning in AI and memory markets offers growth potential for patient investors amid near-term uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
